Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

BACKGROUND: The myocardial effects of phosphodiesterase type 5 inhibitors (PDE5i) have recently received consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear. METHODS: We performed a meta-analysis of randomized, placebo-controlled trials (RCTs) to evaluate t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Giannetta, Elisa, Feola, Tiziana, Gianfrilli, Daniele, Pofi, Riccardo, Dall’Armi, Valentina, Badagliacca, Roberto, Barbagallo, Federica, Lenzi, Andrea, Isidori, Andrea M
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201993/
https://ncbi.nlm.nih.gov/pubmed/25330139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-014-0185-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki